risedronic acid has been researched along with Muscular Dystrophy, Duchenne in 2 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Srinivasan, R | 1 |
| Rawlings, D | 1 |
| Wood, CL | 1 |
| Cheetham, T | 1 |
| Moreno, AC | 1 |
| Mayhew, A | 1 |
| Eagle, M | 1 |
| Guglieri, M | 1 |
| Straub, V | 1 |
| Owen, C | 1 |
| Bushby, K | 1 |
| Sarkozy, A | 1 |
| Bell, JM | 1 |
| Shields, MD | 1 |
| Watters, J | 1 |
| Hamilton, A | 1 |
| Beringer, T | 1 |
| Elliott, M | 1 |
| Quinlivan, R | 1 |
| Tirupathi, S | 1 |
| Blackwood, B | 1 |
1 review available for risedronic acid and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
Topics: Adolescent; Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Calcium; Child; | 2017 |
1 other study available for risedronic acid and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy.
Topics: Administration, Oral; Adolescent; Bone Density; Bone Density Conservation Agents; Child; Cohort Stud | 2016 |